



20
24

ANNUAL REPORT



TABLE OF CONTENTS

| | |
|-------------------------|----|
| Mission..... | 3 |
| From the CEO..... | 4 |
| Core Pillars..... | 6 |
| Leadership..... | 7 |
| Global Impact..... | 8 |
| Strategic Partners..... | 9 |
| Donor Community..... | 11 |
| Patient Impact..... | 16 |
| Financials..... | 18 |

OUR MISSION

TO IMPROVE QUALITY OF LIFE BY
TRANSFORMING THE
UNDERSTANDING, TREATMENT, AND
CARE OF THE OCULAR SURFACE

LETTER FROM THE CEO



It is my privilege to share BostonSight's 2024 Annual Report. This year marked a period of measurable progress, strategic growth, and meaningful impact—all made possible through your support.

In 2024, BostonSight raised more than \$300,000 to advance our vision of a world where no one suffers loss of sight from irregular corneas or ocular surface disease. These funds directly supported our core pillars of Clinical Care, Research and Innovation, Technology, and Education, enabling us to:

- Provide financial assistance to patients who would otherwise be unable to afford sight-saving treatment.
- Conduct and publish industry-leading research, including a 21-year retrospective review of pediatric scleral lenses and a groundbreaking investigation of PROSE® as a drug-delivery device.
- Expand our global reach by growing the BostonSight SCLERAL® network in the U.S., Canada, UK, EU, and Latin America.
- Strengthen our clinical leadership through participation in dozens of educational and professional events across the world, often as invited speakers.
- Invest in technology and manufacturing capacity, including new lens design software evaluations, lab expansion, and lean manufacturing training, allowing us to deliver best-in-class specialty lenses to patients, and deliver them quickly.
- Share our knowledge and experience through FitAcademy™, FitSmart™ events, and the first Global Education Partner Summit which brought together our international partners.

These accomplishments underscore the strength of our model: Integrating clinical expertise, research, engineering, technology, and education to deliver sustainable solutions in corneal care. The true measure of success lies in our impact on patients—individuals who gain not only vision but also quality of life and independence because of your support.

Looking ahead, 2025 will mark the launch of our new five-year strategic plan, which will guide BostonSight toward continued innovation, expanded access to specialty lenses, and strengthened global collaborations. With your ongoing partnership, we are well-positioned to deliver on our mission at greater scale and with greater impact.

On behalf of our board of directors, clinicians, and staff, I would like to extend our sincere gratitude for your commitment to BostonSight. Together, we are advancing the future of ocular health and ensuring that patients worldwide have access to life-changing treatment.

Sincerely,

Sara Yost, MBA
President & CEO

2024 Funds Raised: \$300,000



CORE PILLARS

CLINICAL CARE



We demonstrate how specialty lenses positively impact patient ocular health and quality of life. What we did in 2024:

- Surveyed PROSE patients to document the efficacy of their treatment and impact on their lives
- Broadened sources of fund development through our base and peer-supported events to achieve greater patient financial support
- Implemented quarterly updates to keep donors abreast of clinic developments and mission impact
- Increased awareness of the impact of PROSE and scleral lenses in the treatment of ocular surface disease

RESEARCH AND INNOVATION



We fuel research to influence ocular health benefits of specialty lenses and drive innovation. What we did in 2024:

- Published industry-leading papers, including a 21-Year Retrospective Review of Pediatric Scleral Lenses and Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease
- Attended or were invited speakers at 31 events across ophthalmology and optometry (U.S., Italy, Spain, Portugal, Colombia, and Canada)

TECHNOLOGY



We drive innovation to improve specialty lens technology. What we did in 2024:

- Embarked on a significant evaluation of existing lens design software and identified areas for upgrade in 2025
- Utilized instrument-based topography systems to improve patient outcomes
- Utilized new technology to manufacture lenses with higher-order aberration (HOA) correction
- Created greater manufacturing flexibility, efficiency, and capacity by adding new lathes to our lab, expanding our physical footprint, and implementing lean manufacturing methods

EDUCATION



We push to expand global access to BostonSight lens designs. What we did in 2024:

- Expanded the FitAcademy portfolio of educational events, including adding a program to Latin America with an eye on future international expansion
- Implemented new FitSmart dine and learn events with eye care providers around the U.S.
- Created the first BostonSight SCLERAL Global Education Partner Summit to strengthen our robust international consultation team, which supports BostonSight SCLERAL fitters around the world



BOARD OF DIRECTORS

Pamela Anderson, Esq., Chair

Sara Yost, MBA, President

Donna Desmond, MBA, CPA, Director

Marcus Hughes, Esq., Director

Howard Purcell, OD, Director

Michael Raizman, MD, Director

Ron Remy, MBA, Director

Clifford Scott, OD, MPH, Director

CLINICIANS

Daniel C. Brocks, MD

Chief Medical Officer

Karen G. Carrasquillo, OD, PhD, FAAO, FSLs, FBCLA

Senior VP, Clinical and Professional Affairs

Alan Kwok, OD, FAAO, FSLs

Director of PROSE Network Clinical Relationships

Bitu Asghari, OD, FAAO, FSLs

Associate Director of Clinical Education

Chirag Patel, OD, FAAO

Associate Director of Innovative Technologies

SENIOR STAFF

Sara Yost, MBA, President and CEO

Cheryl Sadeli, MBA, CPA, Chief Financial Officer

Laurel Villers, Chief Business Development Officer

Manoel Carvalho, Director of Lab Operations

Michele Hart, Director of Marketing and Communications

Melinda Kimball, Director of Human Resources

Darlene Riordan, Director of Clinical Operations

Olga Tomashevskaya, Director of Engineering



IMPACT

Eyes Treated: 100,000+
Countries Reached: 40+
Lives Impacted: Countless

STRATEGIC PARTNERS

BostonSight is able to achieve our mission around the world through a network of trusted partners, aligned in vision and shared values.

LV Prasad Eye Institute



LVPEI's mission is to provide equitable and quality eye care to all sections of society. Established in 1987, LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility with multiple locations across India.

Moorfields Eye Hospital
NHS Foundation Trust



The leading provider of eye health services in the UK and a world-class center of excellence for ophthalmic research and education with a reputation, developed over two centuries, for providing the highest quality of ophthalmic care. Moorfields Eye Hospital serves patients throughout the UK.

Conóptica, SL



Conóptica has more than 55 years of experience in the contact lens and optometry industry and provides products, services, and education to eye care professionals to provide effective and tailored visual solutions in Spain, Portugal, and Morocco.

Spectrum
International



A North American-based company that promotes and exports optical goods and services from certified vendors located in strategic geographical locations. Spectrum represents the best laboratories inside and outside of the United States, in over 65 countries across Latin America and the Middle East.



DONORS

LIFETIME GIVING

The Lifetime Giving donor roll recognizes donors who have made significant contributions over the life of their giving.

\$250,000+

Bausch + Lomb World Headquarters
Frank Berry
John W. Henry Family Foundation
Bruce and Holly Johnstone
Thomas Anthony Pappas Charitable Foundation
Michael and Myra McCoy
Nehemias Foundation
Renee Rapaporte
Kate Weingarten

\$100,000 - \$249,999

Wendy Appel
Harry and Honore Birkenruth
Blue Cross Blue Shield of Massachusetts Foundation
Boston Eye Associates
The Charles Evans Foundation
Earmark
Yuriy Fershter
Florence Koplów
John Pevarnik Charitable Trust
Lauren Marino
Valya Shapiro
Enid Starr, Esq.
Tonna Charitable Trust
University of Rochester
Joe and Susan Zienowicz

\$50,000 - \$99,999

Lorne Abony
Anonymous
Competitive Technologies
Michael Moskow
Oculus, Inc.
Perry Rosenthal
Paul Szczygiel

\$25,000 - \$49,999

Amelia Peabody Foundation
Blue Cross Blue Shield of Massachusetts
Indo-American Eye Care Society
Resulticks
Alfoncina Sandoval
Peter Wilson
Yawkey Foundation II

DONORS

VISIONARY CIRCLE OF HOPE

The Visionary Circle of Hope recognizes donors who have given a gift greater than \$1,000 in the giving year.

\$25,000 +

Google, Inc.
Joe and Susan Zienowicz

\$10,000 - \$24,999

Henry and Diane Bisgaier
Eugene and Irena Bonte
Sheryl Erickson
Paul Ferri
Julie Rutenberg
Steven Rutenberg
Kenneth Sawyer

\$5,000 - \$9,999

Pamela Anderson
Bresky Foundation Corporation
Allan and Anne Greenberg
Johnson & Johnson
Joe Martini
Michael B. Raizman
Edward Tanzman

\$1,000 - \$4,999

Brent Archer
Marci Azbell
Alyson Berliner
Harry Branning
Branning Family Charitable Fund
Alicia and Glen Bunnell
Leroy and Jane Crosby
Michael Daily
Gerard De Gunzburg
Michael Dominguez
Mary Dunbrack
Eastern Bank Charitable Foundation
Gary and Susan Fentin
Renard and Mary Francois
Karen Grossman

\$1,000 - \$4,999

Evan Haberman
Donniel and Adina Hartman
JP Morgan Chase and Company
Jay Kelly
Michael P. and Vicki Link
Anna K. Mergen
Latisha Middleton
Carmen Paradis
Howard Purcell
Delia Sattin
Clifford Scott
Jonh Sheskey
George Tonna
Sara and Jason Yost

\$500-\$999

Advanced Micro Devices, Inc.
 Thomas and Nancy Artz
 Bank of America
 Glenn Barest
 Gary Bedrosian
 Stephen Blackwell
 Charles and Sarah Shoaf Cabot
 J. Stephen Collins
 Jean and John Conners
 Dennis Corkum
 Alison Farmer
 Vincent Fratello
 Isabelle Garreaud
 Gene Guselli
 Elise Hauenstein
 David Hobson
 Douglas and Edythe Jablonsky
 Dwayne and Deborah Kepner
 Andrea Knight
 Sherri Kraft
 Paul LeVine
 James MacGregor
 Peter and Robin Muise Fund
 Regeneron Pharmaceuticals, Inc.
 Charles Rehn
 Ron Remy
 Craig and Eileen Yarnell

\$499 and below

Ruth Abelmann
 Rao Addanki
 Gerald and Corinne Adler
 Virginia Alden
 American Endowment Foundation
 Steven Appel
 Norman and Monique Avey
 Bonnie Bader
 Linda Baker
 Mary Bazinet
 Michael Bedrin
 Ed Bennett
 Todd Birkenruth
 Steven Bogatz
 Andrea Bonte Arcuri
 Kathleen Bowen
 Robert Bower
 Joann Bowman
 Helen Bragdon
 Peter G. and Sally Brassard
 Daniel Breen
 Karen Brown
 Robert Brown
 Marcia Burch
 Nancy Busby
 Pamela Cacace-Crepeau
 Ellen Caliendo

\$499 and below

Abby Caplin
 Lynn Carter
 Steven and Kathleen Case
 Selena Chan
 Ross Connelly
 Wendy Cooper
 Christopher Corrigan
 Susan Costello
 Marc and Lynne Craft
 Stephanie Craig
 Will Craig
 Helene Curley
 Jeanee Decenzo
 Sandra DeFrancisco
 John Delude
 Donna Desmond
 Patricia Donahue Hageman
 Sean and Sarah Dorfman
 Michael Dorsett
 Tammy Downes
 Roberta Drury
 Evelyn Duran
 Julie Echols
 Bernard and Lois Edinberg
 Bethany Ellis
 Annette Estefano
 Debby Fenn

\$499 and below

Jeanette Flores
 Jamie and Dennis Floyd
 Angela Ford-Rosenthal
 Tarah Foster
 Dr. Catherine Fuchs
 Kim Gavagan
 Judy Geleerd
 Alexandra Gignac
 Karen Ginsberg
 James Gisonde
 Jillian Giuliano
 Give Lively Foundation
 Penelope Gleason
 Rhonna Goodman
 Gary Green
 Lydia and Ron Greenfield
 Peter Greven
 Greg Hamre
 Beverly Hart
 Michele Hart
 HCA Healthcare
 Kenneth Hengeli
 Mari Hirsh
 Judith Hochstadt
 Lois Horowitz
 Linda Howey
 Marcus Hughes

\$499 and below

Shannon Hughes
 Jeannette Iles
 Deborah S. Jacobs
 David Jacobson
 Frances Jeffries
 Chris and Klavs Jensen
 Dwight Johnson
 Peter Jones
 Jesse Kaminski
 Lyn Kaminski
 Vijay Kannan
 Adolph Karchmer
 Patti Kastner
 Robert and Geraldine Kastner
 Joel Katz
 John and Ellen A. Kelley
 Melinda and Ken Kimball
 Jill Kleeman
 Ellen Knizeski
 Ilene Knopping
 Robert Kopelman
 Ilana Kraus
 Dan and Karen Krugler
 Joanna Kusnierz
 Martine Lalonde
 Chelsea Lane
 Linda Large

\$499 and below

Theresa Laster
 Camille Leblanc
 Keng Lee
 Klimenty Levin
 Martin Levy
 Viola Lundberg
 John J. and Maria Lynch
 Michele Malgieri
 Sandra Mann
 Raymond and Mary Marble
 Richard and Debra Martinez
 Joseph and Patricia Marzetti
 Matthew and Margarethe Mashikian
 Daniel and Sheila Massarelli
 Mark and Catherine Mathers
 Jack Mayer
 Mark and Sandra Mazur
 Karen McAnern
 Joseph McKeon
 Nancy Miller
 Lewis Mitchard
 McKinley Mitchell
 Scott Nascimento
 Barbara Nelson
 Patricia Nestler
 Bien Nguyen
 Diane Norton

\$499 and below

Irina Norton
 Maria Noto
 Jayme Nozzi
 Richard and Patricia O'Brien
 Eli Okrant
 Barbara Oravec
 Miriam L. Ornstein
 Kathy Owen
 Palo Alto Networks
 Gina Parkinson
 Linda Patti
 Nancy Paull Nida
 Ken Payne
 Paypal Giving
 Beverly Peiser
 Mary Peled
 Thomas Perosky
 Teri Piatt
 Ellen Pichey
 Tamela Pink
 Stephanie Pisano
 Joan Porco
 Karen Pozzi
 Daniela Prodanovic
 Geraldine Radzanowski
 Anne Redman-Lyon

\$499 and below

Linda Reichert
 David Rosen
 Leonard Rosenthal
 Barbara Rostosky
 Mark Roux
 James Ruby
 T. Michael Russo
 Robert Ryan
 Jacqueline Sabourin
 Shahzad Saleem
 Seth Salley
 Tim Sanders
 Monserrate Santiago
 Dawn Saunders
 Helga Seiler
 Ruchika Sethi
 Robert Seyler
 Sue Sharer
 Donna Sherman
 Patrick Simard
 Peggy Sisselman
 Amy Smith
 Darlene Smolak
 Rosalind Spigel
 Howard Stoner
 Patricia Szymkiewicz

\$499 and below

Nancy Tepper
 Alfred Thoman
 Emily Tourtillotte
 Robert VanGrol
 Tatleen Vassell
 Judith Velez
 Laurel and Paul Villers
 Simran Vohra
 Dorothy Waldron
 Michael Watson
 Jonathan Weber
 Jerome Weinstein
 Ma'lis Wendt
 Milan Whalen
 Norman Wilikofsky
 James Willis
 John Wilson
 Manira Wilson-Bassett
 William Wright
 Daniel Wywoda
 Jeremie Xatruch
 Brittany Yelle
 Sandra Yelle
 Janice Yost

Scleral lenses and their impact on ALS patients



Jacob (center) with his parents.

When 23-year-old Jacob Harper from Winfield, West Virginia, first heard the words “You have ALS,” in March 2022, he and his father sat in shock. Neither had a clear understanding of what the diagnosis meant. His mother, however, turned pale—she knew the weight of those three letters. Amyotrophic lateral sclerosis, or ALS, is a relentless disease. For Jacob, it was not just ALS but an ultra-rare genetic version, linked to the P525L FUS mutation. Doctors told him to expect only one to three years.

Jacob, once an avid outdoorsman who loved hunting, fishing, and working as a machinist and a welder, suddenly faced a future of increasing paralysis and loss. Yet, through determination, faith, and access to an experimental drug called ION363—nicknamed “Jacifusen”—he has lived beyond those initial predictions. Even as the disease advanced, Jacob and his family found new ways to fight for quality of life.

One of the most unexpected breakthroughs came not from a drug or machine, but from a pair of lenses.

As ALS progressed, Jacob eventually lost the ability to move his eyes. He could no longer blink, and his eyelids wouldn’t stay open. Severe dry eye followed, leaving his eyes painfully irritated and threatening to take away his ability to watch television, enjoy car rides, or even communicate. At times, his parents resorted to using cosmetic tape to hold his eyelids open. It was an exhausting, imperfect solution that underscored how fragile his remaining independence had become.

Enter scleral lenses. Traditionally used for patients with corneal disease or extreme dry eye, these specialized contact lenses are larger than normal and vault over the eye, creating a reservoir of fluid that bathes the cornea. Jacob’s care team at The Ohio State University had never tried them in someone with ALS before, but they were willing to innovate. Working with Dr. Stephanie Pisano and her team, including a dedicated resident, Dr. Shihij Takoo, Jacob went through multiple fittings to find lenses that worked. They had to account for astigmatism, depth, and comfort, making careful adjustments along the way.

The impact was immediate. With the scleral lenses in place, Jacob’s eyes could stay open and moist, protected from damage and discomfort.

continued on next page


PATIENT IMPACT

Combined with cosmetic tape, the lenses allowed him to keep his eyes open long enough to enjoy daily life again and, most importantly, stay engaged with the people he loves. His father calls the lenses “a blessing,” explaining, “I don’t know what we would do if it had not been for the scleral lenses. In a world where we had already lost almost everything, and we only had communication left, these lenses made sure we were able to hang on to this piece of dignity.”

Communication is one of the cruelest battlegrounds in ALS. Before his eye paralysis, Jacob was lightning-fast on an eye-gaze computer system, astonishing his speech therapist with his speed. He could email, text, even shop online almost as quickly as before his diagnosis. In fact, it was almost as if his family could have regular conversations with Jacob. As his voice deteriorated, Jacob’s family connected with Bridging Voice, a nonprofit based in New York City, who assists ALS families with communication technology. They were put in touch with ElevenLabs, who uses clips of person’s voice to create an electronic voice. Using videos, they created an AI duplicate that sounded almost identical to Jacob.

When he lost the ability to move his eyes, that option disappeared. Today, he communicates using a neuro-node system connected to his leg muscles. Though slower, it still allows him to share his thoughts and direct his smart home devices. Today, scleral lenses make it possible to keep his eyes open, protected, and moisturized, and interact with his environment, preserving the vital connection between his mind and the outside world.

For the Harper family, the lenses are more than a medical tool. They are a bridge. They have enabled Jacob to remain present in



“I don’t know what we would do if it had not been for the scleral lenses. In a world where we had already lost almost everything, and we only had communication left, these lenses made sure we were able to hang on to this piece of dignity.”

everyday moments, whether watching movies with his parents, listening to vinyl records, or taking long drives, where his father straps him into his beloved Mustang and takes him out on the open road.

ALS is a disease defined by relentless loss: the loss of movement, speech, independence, and time. But in Jacob’s case, scleral lenses hit the pause button, allowing him to maintain communication longer. They offer comfort, vision, and dignity in the face of one of life’s harshest challenges. And in doing so, they keep open a window to the world that would have otherwise closed too soon.

FINANCIALS



\$9.72M

Total revenue

\$9.26M

Total expenses

INCOME AND EXPENSES (\$ in 000's)

| INCOME | 12/31/2024 | 12/31/2023 |
|----------------------------|-----------------|-----------------|
| Network clinic revenue | \$ 4,952 | \$ 4,460 |
| Patient services | 3,994 | 3,717 |
| Contributions and grants | 452 | 342 |
| In-kind and other | 227 | 342 |
| Capital grant | 98 | 102 |
| Total Income | \$ 9,722 | \$ 8,964 |
| EXPENSES | | |
| Operating and research | 7,789 | 7,104 |
| Education | 159 | |
| General and administrative | 1,261 | 1,557 |
| Fundraising | 54 | 66 |
| Total Expenses | \$ 9,264 | \$ 8,727 |
| Net Income | \$ 458 | \$ 237 |

The information has been extracted from the IRS form 990 and the financial statements of Boston Foundation for Sight for the years ending December 31, 2023, and 2024 that were audited by the independent certified public accounting firm AAFCPAs.

BALANCE SHEET (\$IN 000'S)

ASSETS

Current assets:

| | 12/31/2024 | 12/31/2023 |
|---------------------------------------|-----------------|-----------------|
| Cash and cash equivalents | \$ 2,607 | \$ 2,803 |
| Current portion of restricted cash | 26 | 22 |
| Accounts Receivable - patients | 886 | 957 |
| Accounts Receivable - network clinics | 446 | 479 |
| Accounts Receivable - other | 56 | 30 |
| Inventory | 386 | 423 |
| Prepaid expenses and other | 128 | 118 |
| Total current assets | \$ 4,534 | \$ 4,832 |

Other assets:

| | | |
|---|-------|-------|
| Property and equipment, net | 2,909 | 2,348 |
| Right-of-use assets - Operating | 2,244 | 2,546 |
| Restricted cash, net of current portion | 185 | 185 |
| Deposits | 33 | 33 |

Total assets:

| | |
|-----------------|-----------------|
| \$ 9,904 | \$ 9,943 |
|-----------------|-----------------|

LIABILITIES AND NET ASSETS

Current liabilities:

| | | |
|--|--------|--------|
| Accounts payable and accrued expenses | \$ 829 | \$ 816 |
| Current portion of note payable | 132 | 202 |
| Current portion of operating lease liabilities | 467 | 456 |
| Deferred revenue | 792 | 817 |

Total current liabilities:

| | |
|-----------------|-----------------|
| \$ 2,220 | \$ 2,290 |
|-----------------|-----------------|

Operating lease liabilities, net of current portion

| | |
|--------------|--------------|
| 1,981 | 2,271 |
|--------------|--------------|

Notes Payable, net of current portion

| | |
|---------------|---------------|
| \$ 386 | \$ 523 |
|---------------|---------------|

Total liabilities:

| | |
|--------------|--------------|
| 4,588 | 5,084 |
|--------------|--------------|

Net assets:

| | | |
|----------------------------|----------|----------|
| Without donor restrictions | \$ 5,106 | \$ 4,652 |
| With donor restrictions | 210 | 207 |

Total net assets:

| | |
|-----------------|-----------------|
| \$ 5,317 | \$ 4,859 |
|-----------------|-----------------|

Total liabilities and net assets:

| | |
|-----------------|-----------------|
| \$ 9,904 | \$ 9,943 |
|-----------------|-----------------|



BostonSight
464 Hillside Avenue, Suite 205
Needham, MA 02494
781-726-7337

www.bostonsight.org
info@bostonsight.org